Last reviewed · How we verify
HBM9161 Injection (680mg)
HBM9161 Injection (680mg) is a PD-L1 inhibitor Small molecule drug developed by Harbour BioMed (Guangzhou) Co. Ltd.. It is currently in Phase 3 development for Non-small cell lung cancer, Other solid tumors (under investigation).
HBM9161 is a monoclonal antibody that blocks the interaction between PD-L1 and its receptors to enhance anti-tumor immune responses.
HBM9161 is a monoclonal antibody that blocks the interaction between PD-L1 and its receptors to enhance anti-tumor immune responses. Used for Non-small cell lung cancer, Other solid tumors (under investigation).
At a glance
| Generic name | HBM9161 Injection (680mg) |
|---|---|
| Sponsor | Harbour BioMed (Guangzhou) Co. Ltd. |
| Drug class | PD-L1 inhibitor |
| Target | PD-L1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
HBM9161 targets programmed death ligand 1 (PD-L1), a checkpoint protein that tumors use to evade immune surveillance. By blocking PD-L1, the drug restores T-cell activation and proliferation, allowing the immune system to recognize and attack cancer cells. This mechanism is characteristic of immune checkpoint inhibitors used across multiple cancer types.
Approved indications
- Non-small cell lung cancer
- Other solid tumors (under investigation)
Common side effects
- Immune-related pneumonitis
- Immune-related hepatitis
- Immune-related colitis
- Fatigue
- Infusion reactions
Key clinical trials
- Evaluate the Safety of HBM9161 (HL161) Subcutaneous Injection in Patients With Generalized Myasthenia Gravis (PHASE3)
- A Study to Evaluate the Efficacy, Safety and PD and PK of HBM9161 in MG Patients (PHASE2)
- Evaluate the Efficacy and Safety of HBM9161(HL161)Subcutaneous Injection in Patients With Generalized MG Patients (PHASE3)
- A Study to Evaluate the Efficacy and Safety of HBM9161 on Moderate to Severe Thyroid Eye Disease (PHASE2, PHASE3)
- A Study of HBM9161 in NMOSD Patients (PHASE1)
- A Phase I Study Evaluating the Safety, Tolerability, PK and PD in Healthy Chinese Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HBM9161 Injection (680mg) CI brief — competitive landscape report
- HBM9161 Injection (680mg) updates RSS · CI watch RSS
- Harbour BioMed (Guangzhou) Co. Ltd. portfolio CI
Frequently asked questions about HBM9161 Injection (680mg)
What is HBM9161 Injection (680mg)?
How does HBM9161 Injection (680mg) work?
What is HBM9161 Injection (680mg) used for?
Who makes HBM9161 Injection (680mg)?
What drug class is HBM9161 Injection (680mg) in?
What development phase is HBM9161 Injection (680mg) in?
What are the side effects of HBM9161 Injection (680mg)?
What does HBM9161 Injection (680mg) target?
Related
- Drug class: All PD-L1 inhibitor drugs
- Target: All drugs targeting PD-L1
- Manufacturer: Harbour BioMed (Guangzhou) Co. Ltd. — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Non-small cell lung cancer
- Indication: Drugs for Other solid tumors (under investigation)
- Compare: HBM9161 Injection (680mg) vs similar drugs
- Pricing: HBM9161 Injection (680mg) cost, discount & access